FORT LAUDERDALE, Fla. — A senolytic therapy represents a novel approach to treating diabetic macular edema and wet age-related macular degeneration, according to a speaker at the Retina World Congress. Raj Maturi, MD, presented data from a phase 1 study exploring the safety and efficacy of UBX1325 (Unity Biotechnology).
Related Posts
Senolytics in the News
- Fighting aging with immune checkpoint blockade
- Despite Their Scary Name, Some ‘Zombie’ Cells May Not Be All Bad
- Focus on frailty: New senolytic holds potential for sarcopenia treatment
- Progress in Emerging Alzheimer’s Therapeutics Based on Biology of Aging to be Highlighted in Session Moderated by Alzheimer’s Drug Discovery Foundation (ADDF) at 2022 Clinical Trials on Alzheimer’s Disease Conference
- Senolytic treatment shows promise in DME, wet AMD